An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Source · ClinicalTrials.gov: peptide AND aging
TLDR
A ClinicalTrials.gov listing describes a recruiting phase 2 study comparing adalimumab with placebo in people with idiopathic REM sleep behavior disorder. The study will assess whether adalimumab can reduce or prevent progression of synuclein-related neurodegeneration, using changes in a Parkinson disease-related imaging pattern as its primary endpoint.
- 01The trial is recruiting participants with idiopathic REM sleep behavior disorder.
- 02The primary endpoint is change from baseline in the Parkinson Disease Related Pattern, assessed using FDG PET imaging.
- 03The excerpt reports no trial results.
Why it matters Editorial
The study investigates a potential approach to preventing neurodegenerative progression, but the excerpt does not establish a benefit or mention any peptides on the provided list.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.